The North America Theranostics Market revenue displayed strong growth from 2020 to 2025, rising from 1,250 million USD to 2,020 million USD, driven by escalating investments in personalized medicine and new product launches. Projections through 2035 forecast sustained upward momentum, with market value expected to surpass 5,560 million USD by the end of the period. This robust trajectory is attributable to continuous R&D, partnerships among key players, and increasing clinical adoption of comprehensive theranostic platforms in both oncology and non-oncology domains. The market’s resilience against economic volatility and expanding reimbursement coverage further solidify its long-term potential.
Read More - https://bussinessinsights.com/research-report/north-america-theranostics-market
Oncology dominates the North America Theranostics Market by application in 2025, holding 58% share, underpinned by increasing cancer prevalence and robust clinical research investments. Cardiovascular diseases account for 14%, leveraging recent advances in molecular diagnostics and targeted therapy. Neurological disorders (11%) are also gaining traction as theranostic products for Alzheimer’s and Parkinson’s enter late-stage development. Immunological and infectious diseases represent emerging segments at 9% and 6% respectively, with others encompassing a minor share. Overall, oncology remains at the forefront due to its established use cases and reimbursement models, while expansion into other indications is poised to accelerate as new biomarkers and companion diagnostics receive regulatory endorsement.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-theranostics-market
Who are the key players in North America Theranostics Market industry?
The top five key players in the North America theranostics market include GE Healthcare, Siemens Healthineers, Roche Diagnostics, Thermo Fisher Scientific, and Bayer AG. These companies are recognized for their innovative diagnostic and therapeutic solutions, strong research and development capabilities, and robust market presence across the region.
What is the North America Theranostics Market growth?
The North America theranostics market is witnessing significant growth, driven by increasing adoption of personalized medicine and targeted therapies. For example, GE Healthcare has recently expanded its theranostics portfolio, leading to a projected compound annual growth rate (CAGR) of over 10% from 2023 to 2030.
Which segment accounted for the largest North America Theranostics Market share?
The oncology segment accounted for the largest share of the North America theranostics market. This is due to a high prevalence of cancer and the increasing use of theranostics for personalized cancer therapies, particularly in prostate and breast cancer applications, driving demand for advanced diagnostic and treatment solutions.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com